Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599581 | 0.98 | MAPK1 (0.61) | MAPK1ITGB3ITGA2BPRSS1F10 | |
| SCHEMBL14599527 | 0.98 | MAPK1 (0.61) | MAPK1ITGB3ITGA2BPRSS1F10 | |
| SCHEMBL14599618 | 0.98 | MAPK1 (0.61) | MAPK1ITGB3ITGA2BPRSS1F10 | |
| SCHEMBL14599582 | 0.98 | MAPK1 (0.61) | MAPK1ITGB3ITGA2BPRSS1F10 | |
| SCHEMBL14519316 | 0.90 | NPC1 (0.54) | MAPK1ITGB3ITGA2BPRSS1F10 | |
| SCHEMBL9030474 | 0.90 | L3MBTL1 (0.59) | ITGB3ITGA2BPRSS1F10ALDH1A1 | |
| SCHEMBL28947192 | 0.85 | F10 (0.54) | ITGB3ITGA2BPRSS1F10F2 | |
| SCHEMBL2344986 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BPRSS1F10F2 | |
| SCHEMBL7328394 | 0.85 | MAPK1 (0.63) | MAPK1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL8408094 | 0.85 | MAPK1 (0.68) | MAPK1ITGB3ITGA2BF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262223-B2 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-28 | — | — | US | claimed |
| US-20050182118-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-08-18 | — | — | US | claimed |
| US-7262223-B2 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-28 | — | — | US | disclosed |
| US-7262223-B2 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182118-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | MAPK1 2258/4885ITGB3 3940/4885ITGA2B 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.